SUMO2 and cardiac hypertrophy: Finally, as a proof of principle for an in vivo relevance of the proposed mechanism, we show that SUMO2 causes cardiac hypertrophy and contractile dysfunction in a sumoylation-independent manner in vivo, by means of AAV9 gene-transfer technology.